The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
Corner Brook city council spent close to $9,000 less on travel
St. John's RNC looking for missing 33-year-old woman
ParksNL launches reservations next week for the 2025 Camping season
Funding has been approved to plan for 13 new affordable units in Corner Brook
Bayfm News features Sarah Parsons, NDP candidate for Long Range Mountains
